No Data
No Data
Hubei Jumpcan Pharmaceutical (600566.SH): the company's products are not included in the Anhui Provincial procurement scope.
On September 12, Hubei Jumpcan Pharmaceutical (600566.SH) stated on the interactive platform that the company's products have not been included in the Anhui Province centralized procurement scope. The company closely monitors the changes and progress of the centralized procurement policy and actively prepares for it.
Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Jumpcan Pharmaceutical Gets China Nod for Anti-Stomach Ulcer Tablets
Hubei Jumpcan Pharmaceutical (600566.SH): Lafutidine tablets obtained pharmaceutical registration certificate.
On September 4th, GeLonghui reported that Hubei Jumpcan Pharmaceutical (600566.SH), a wholly-owned subsidiary of Hubei Jumpcan Pharmaceutical Group Co., Ltd., has received the Drug Registration Certificate for Lafutidine issued by the National Medical Products Administration. Lafutidine is a new type of histamine H2 receptor antagonist that inhibits gastric acid secretion and enhances mucosal protective factors.
Hubei Jumpcan Pharmaceutical (600566.SH): Has repurchased a total of 0.1805 million shares.
On September 3, GuoLongHui announced that as of August 31, 2024, Hubei Jumpcan Pharmaceutical (600566.SH) has repurchased a total of 180,500 shares through centralized bidding trading, accounting for 0.02% of the company's total share capital. The highest purchase price was 29.00 yuan/share and the lowest purchase price was 27.29 yuan/share. The total amount paid was RMB 5,004,978 (excluding transaction fees).
Do Hubei Jumpcan Pharmaceutical's (SHSE:600566) Earnings Warrant Your Attention?
No Data
No Data